JP7480135B2 - 新規使用 - Google Patents

新規使用 Download PDF

Info

Publication number
JP7480135B2
JP7480135B2 JP2021521516A JP2021521516A JP7480135B2 JP 7480135 B2 JP7480135 B2 JP 7480135B2 JP 2021521516 A JP2021521516 A JP 2021521516A JP 2021521516 A JP2021521516 A JP 2021521516A JP 7480135 B2 JP7480135 B2 JP 7480135B2
Authority
JP
Japan
Prior art keywords
pde1 inhibitor
replacement therapy
alkyl
disease
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505471A5 (https=
JP2022505471A (ja
Inventor
イー デイビス，ロバート
イー バノーバー，キンバリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2022505471A publication Critical patent/JP2022505471A/ja
Publication of JP2022505471A5 publication Critical patent/JP2022505471A5/ja
Application granted granted Critical
Publication of JP7480135B2 publication Critical patent/JP7480135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021521516A 2018-10-21 2019-10-21 新規使用 Active JP7480135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748517P 2018-10-21 2018-10-21
US62/748,517 2018-10-21
PCT/US2019/057260 WO2020086481A1 (en) 2018-10-21 2019-10-21 Novel uses

Publications (3)

Publication Number Publication Date
JP2022505471A JP2022505471A (ja) 2022-01-14
JP2022505471A5 JP2022505471A5 (https=) 2022-10-28
JP7480135B2 true JP7480135B2 (ja) 2024-05-09

Family

ID=70331921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521516A Active JP7480135B2 (ja) 2018-10-21 2019-10-21 新規使用

Country Status (11)

Country Link
US (2) US12194042B2 (https=)
EP (1) EP3866808A4 (https=)
JP (1) JP7480135B2 (https=)
KR (1) KR20210080418A (https=)
CN (1) CN113194955A (https=)
AU (1) AU2019364274C1 (https=)
BR (1) BR112021007571A2 (https=)
CA (1) CA3117148A1 (https=)
IL (1) IL282396A (https=)
MX (1) MX2021004531A (https=)
WO (1) WO2020086481A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210614A1 (en) * 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Organic compounds
EP4413980A3 (en) 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
MX2023008755A (es) * 2021-01-27 2023-08-02 Intra Cellular Therapies Inc Cristales de sal.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017527598A (ja) 2014-09-17 2017-09-21 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 化合物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
RS52166B (sr) 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
TW201206937A (en) * 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US10918628B2 (en) * 2016-10-11 2021-02-16 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017527598A (ja) 2014-09-17 2017-09-21 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 化合物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting，2018年10月17日，［令和５年１０月１６日検索］、インターネット<https://ir.intracellulartherapies.com/node/10026/pdf>

Also Published As

Publication number Publication date
US12194042B2 (en) 2025-01-14
CN113194955A (zh) 2021-07-30
US20250090536A1 (en) 2025-03-20
AU2019364274A1 (en) 2021-06-03
EP3866808A4 (en) 2023-04-12
US20210379072A1 (en) 2021-12-09
BR112021007571A2 (pt) 2021-07-27
CA3117148A1 (en) 2020-04-30
AU2019364274C1 (en) 2025-04-10
EP3866808A1 (en) 2021-08-25
IL282396A (en) 2021-06-30
KR20210080418A (ko) 2021-06-30
AU2019364274B2 (en) 2024-10-17
JP2022505471A (ja) 2022-01-14
WO2020086481A1 (en) 2020-04-30
MX2021004531A (es) 2021-09-10

Similar Documents

Publication Publication Date Title
US20250090536A1 (en) Uses
JP7579888B2 (ja) 治療用固形製剤
EP2081431B1 (en) Organic compounds
EP2167066B1 (en) Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders
JP6696904B2 (ja) 製剤および医薬組成物
JP7749896B2 (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
EP2624821B1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
JPWO2012067111A1 (ja) ＰＫＣ−ε活性化剤
US20140271890A1 (en) Controlled-release pharmaceutical composition
US20210369715A1 (en) Novel uses
RU2836384C2 (ru) Новые применения
HK40057178A (en) Novel uses
US20230355625A1 (en) Methods of treatment
US20230071934A1 (en) Novel uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240424

R150 Certificate of patent or registration of utility model

Ref document number: 7480135

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150